Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07820241) titled 'Long-term Immune Persistence of a Bivalent HPV Vaccine in Females From Study 311-HPV-1004' on Sept. 10.

Study Type: Observational

Primary Sponsor: Shanghai Zerun Biotechnology Co.,Ltd

Condition: Human Papillomavirus Infection

Intervention: Biological: Bivalent Human Papillomavirus Vaccine (Types 16 and 18, Pichia pastoris)

Recruitment Status: Not recruiting

Date of First Enrollment: March 25, 2023

Target Sample Size: 348

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07820241

Disclaimer: Curated by HT Syndication....